Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation

Reuters

10/17

Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation

Protalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576375270"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576375270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576375270?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576375270","market":"fut","top_or_hot":-1,"title":"Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-17 20:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLX","symbol_name":"Protalix BioTherapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL1vNnGB:1","article_id":"2576375270","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576375270","pubTimestamp":1760702997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLX":"Protalix BioTherapeutics Inc","BK4139":"生物科技"},"translate_title":"Protalix BioTherapeutics在最新的公司演示中重点介绍了罕见病药物管道和新的痛风疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLX":0.9},"content_text":"Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation\n    \n\nProtalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}